<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03472651</url>
  </required_header>
  <id_info>
    <org_study_id>17686A</org_study_id>
    <nct_id>NCT03472651</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study to Compare Two Formulations of Deanxit®</brief_title>
  <official_title>Interventional, Randomized, Single Dose, Open-label, Crossover, Bioequivalence Study in Healthy Men and Women to Compare Two Pharmaceutical Formulations of Flupentixol/Melitracen (Deanxit®) - in Fasted and Fed Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lundbeck A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>H. Lundbeck A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to establish bioequivalence of flupentixol/meltracen, between a
      new film-coated tablet formulation and the marketed coated tablet formulation (Deanxit®),
      administered single dose in fasted and fed condition
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2018</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC0-72h: flupentixol</measure>
    <time_frame>from zero to 72 hours post-dose</time_frame>
    <description>the area under the flupentixol plasma concentration-time curve</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax: flupentixol</measure>
    <time_frame>from zero to 72 hours post-dose</time_frame>
    <description>maximum observed plasma concentration of flupentixol</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-72h: melitracen</measure>
    <time_frame>from zero to 72 hours post-dose</time_frame>
    <description>the area under the melitracen plasma concentration-time curve</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax: melitracen</measure>
    <time_frame>from zero to 72 hours post-dose</time_frame>
    <description>maximum observed concentration of melitracen</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Cohort A1 Fasted condition</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in cohort A1 will be administered the Investigational Medicinal Product in a fasted state, 30 subjects per cohort</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A2 Fed condition</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in cohort A2 will be administered the Investigational Medicinal Product in a fed state, 30 subjects per cohort</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>test treatment: flupentixol/melitracen</intervention_name>
    <description>0.5 mg flupentixol and 10 mg melitracen, film-coated tablet, single dose</description>
    <arm_group_label>Cohort A1 Fasted condition</arm_group_label>
    <arm_group_label>Cohort A2 Fed condition</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>reference treatment: flupentixol/melitracen</intervention_name>
    <description>0.5 mg flupentixol and 10 mg melitracen, coated tablet, single dose</description>
    <arm_group_label>Cohort A1 Fasted condition</arm_group_label>
    <arm_group_label>Cohort A2 Fed condition</arm_group_label>
    <other_name>Deanxit®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy men and women ≥18 and ≤55 years of age with a body mass index (BMI) of ≥ 18.5
             and ≤ 28 kg/m2.

          -  Women must be non-pregnant and non-lactating
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Email contact via H. Lundbeck A/S</last_name>
    <role>Study Director</role>
    <affiliation>LundbeckClinicalTrials@Lundbeck.com</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Email contact via H. Lundbeck A/S</last_name>
    <phone>+45 36301311</phone>
    <email>LundbeckClinicalTrials@Lundbeck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>CN1036 Shijitan Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Email contact via H. Lundbeck A/S</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 14, 2018</study_first_submitted>
  <study_first_submitted_qc>March 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 21, 2018</study_first_posted>
  <last_update_submitted>March 14, 2018</last_update_submitted>
  <last_update_submitted_qc>March 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Flupenthixol</mesh_term>
    <mesh_term>Flupenthixol decanoate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

